Key result
Arachidonic acid-induced platelet aggregation >20% identified fewer patients with high on-aspirin treatment platelet reactivity compared to serum TxB2 >3.1 ng/ml.
Why the study?
Does AA-induced platelet aggregation agree with serum TxB2 in identifying high on-aspirin treatment platelet reactivity?
Observational (n=180)
Does AA-induced platelet aggregation agree with serum TxB2 in identifying high on-aspirin treatment platelet reactivity?
AA-induced platelet aggregation and serum TxB2 assays show low agreement in identifying high on-aspirin treatment platelet reactivity, with the former identifying fewer patients.
Answers are grounded in this paper and cite their sources.
Discordant platelet tests for aspirin sensitivity warrant clinical caution; leaves open validation of reliable HAPR markers.
Serum thromboxane-B2 (TxB2), together with arachidonic acid (AA)-induced platelet aggregation, are, at the moment, the most used tests to identify patients displaying high on-aspirin treatment platelet reactivity (HAPR). Both tests are specific for aspirin action on cyclooxygenase-1. While the correlation between serum TxB2 assay and clinical outcome is established, data are conflicting with regard to aspirin treatment and a possible association with AA-stimulated platelet markers and clinical outcome. To understand such discrepancy, we performed a retrospective study to compare both assays. We collected data from 132 patients receiving a daily dose of aspirin (100 mg/day) and data from 48 patients receiving aspirin on alternate days. All Patients who received a daily dose of aspirin were studied for AA-induced platelet aggregation together with serum TxB2 levels and AA-induced TxB2 formation was also studied in 71 patients out of entire population. Consistent with recommendations in the literature, we defined HAPR by setting a cut-off point at 3.1 ng/ml for serum levels of thromboxane B2 and 20% for AA-induced platelet aggregation. According to this cut-off point, we divided our overall population into two groups: (1) TxB2 < 3.1 ng/ml and (2) TxB2 > 3.1 ng/ml. We found low agreement between such tests to identify patients displaying HAPR. Our results show that AA-induced platelet aggregation >20% identify a smaller number of HAPR patients in comparison with TxB2. A good correlation between serum TxB2 and arachidonic acid-induced TxB2 production was found (r = 0.76619).
No takes yet. Share an insight, caveat, or question.
Temperilli et al. (2015) conducted an observational in High on-aspirin treatment platelet reactivity (HAPR) (n=180). Arachidonic acid (AA)-induced platelet aggregation vs. Serum thromboxane-B2 (TxB2) assay was evaluated on Agreement between tests to identify high on-aspirin treatment platelet reactivity (HAPR) (r = 0.76619). Arachidonic acid-induced platelet aggregation >20% identified fewer patients with high on-aspirin treatment platelet reactivity compared to serum TxB2 >3.1 ng/ml.
Synapse has enriched 10 related papers. Consider them for comparative context: